Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Oral Maxillofac Surg ; 72(5): 858-67, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24642135

RESUMO

PURPOSE: Oral anticoagulant therapy (OAT) patients have international normalized ratio (INR) safety windows for oral surgery, the lower limit of which is determined by the thromboembolic risk, with the upper limit typically 3.0. We sought to assess whether these limits will also be true with comorbidities that favor bleeding, such as diabetes, liver disease, and chronic renal failure. MATERIALS AND METHODS: The study was designed for 500 consecutive extractions. Patients with an INR greater than 3.0 were switched to heparin and used as controls. The primary outcome was the incidence of bleeding with the need for reoperation, in connection with 3 principal predictors: the INR, reasons for OAT, and comorbidity type. Continuous variables were analyzed using the Mann-Whitney U test and categorical variables using χ2 or Fisher's exact test. Statistical significance was set at P < .05. The reliability of the INR as a bleeding predictor was assessed using receiver operating characteristic (ROC) curves. RESULTS: Extractions in patients receiving OAT without comorbidities had a success rate of 99.7% against severe bleeding. Despite equivalent INR values, patients with comorbidities had a significantly lower rate (81.3%, P < .001). For these patients, the ROC curve procedure indicated lower INR upper limits, 2.8 for mechanical heart prosthesis subjects and 2.3 for all others. Among the comorbidities, diabetes was associated with the greatest frequency of bleeding (31%) compared with liver disease (15%) and kidney failure (11%). CONCLUSIONS: Patients with comorbidities should be advised to bring their INR within narrower safety windows (upper limit of 2.5 to 2.8 for mechanical prosthesis and 2.0 to 2.3 otherwise) or be switched to heparin. Alternatively, we propose applying to the socket, a platelet-rich growth factor preparation to foster hemostasis.


Assuntos
Anticoagulantes/uso terapêutico , Doença Crônica , Hemorragia Bucal/etiologia , Hemorragia Pós-Operatória/etiologia , Extração Dentária , Adulto , Idoso , Idoso de 80 Anos ou mais , Área Sob a Curva , Complicações do Diabetes , Feminino , Fibrina/uso terapêutico , Seguimentos , Próteses Valvulares Cardíacas , Hematoma/etiologia , Hemostáticos/uso terapêutico , Heparina/uso terapêutico , Humanos , Coeficiente Internacional Normatizado , Hepatopatias/complicações , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Curva ROC , Insuficiência Renal/complicações , Tromboembolia/prevenção & controle , Alvéolo Dental/cirurgia , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...